Brain News and Research

RSS

The human brain is the center of the human nervous system and is a highly complex organ. Enclosed in the cranium, it has the same general structure as the brains of other mammals, but is over three times as large as the brain of a typical mammal with an equivalent body size.

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

Eric Boerwinkle, Ph.D., a professor at The University of Texas Health Science Center at Houston, has received a $26 million federal stimulus grant to lead an effort to pinpoint genetic factors affecting the risk of heart, lung and blood diseases.

12 Oct 2009

Hyper-SAGE with MRI sensitivity, a promising tool for in vivo diagnostics and molecular imaging

A new technique in Magnetic Resonance Imaging dubbed "Hyper-SAGE" has the potential to detect ultra low concentrations of clincal targets, such as lung and other cancers. Development of Hyper-SAGE was led by one of the world's foremost authorities on MRI technology, Alexander Pines, a chemist who holds joint appointments with the Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California, Berkeley.

12 Oct 2009

Three hundred participants sought for world-first study to determine shared biological basis for psychotic illnesses

For the first time, sufferers of schizophrenia and bipolar disorder are being brought together in a major new study investigating the diseases' common genetic causes and manifestations.

11 Oct 2009

Learning new tasks causes changes in spontaneous brain activity patterns: Study

Spontaneous brain activity formerly thought to be "white noise" measurably changes after a person learns a new task, researchers at Washington University School of Medicine in St. Louis and the University of Chieti, Italy, have shown.

9 Oct 2009

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo

9 Oct 2009

NIH grant to the University of Central Florida to conduct research on aphasia

A new University of Central Florida study could help tens of thousands of Chinese-Americans who have difficulty speaking after they suffer from strokes or other illnesses.

9 Oct 2009

Hispanic children with brain tumors rarely get high-quality treatment than other children: Study

Hispanic children diagnosed with brain tumors get high-quality treatment at hospitals that specialize in neurosurgery far less often than other children with the same condition, potentially compromising their immediate prognosis and long-term survival, according to research from Johns Hopkins published in October's Pediatrics.

9 Oct 2009

New York Governor participates in roundtable discussion on stem cell research

Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today. Allen M. Spiegel, M.D., the Marilyn and Stanley M. Katz Dean of Einstein, and eight stem cell researchers discussed advances in medical therapies and treatments that Einstein scientists have been investigating since receiving more than $14 million in State funding for stem cell research.

9 Oct 2009

TGen selected to conduct cancer experiments using advanced computer simulations

SAIC-Frederick Inc., under its prime contract with the National Cancer Institute, has named the Translational Genomics Research Institute (TGen) as one of five national centers selected to conduct cancer experiments using advanced computer simulations.

9 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

Therapeutic hypothermia after CPR improves survival and lessens brain damage

Cooling a person's body within six hours of cardiac arrest with successful CPR might improve survival and lessen brain damage, according to a new Cochrane review.

9 Oct 2009

Study raises concerns on long-term consequences of neonatal caffeine administration on brain development

An F1000 evaluation looks at a Canadian study on how giving caffeine to newborn rats has a long-lasting and detrimental effect on sleep and breathing in adulthood

9 Oct 2009

New findings highlight potential role of copper in Alzheimer's disease

New research has shown that there could be a protective role for copper in Alzheimer's disease.

9 Oct 2009

Premature aging of immune system develops amyotrophic lateral sclerosis

Premature aging of the immune system appears to play a role in the development of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to research scientists from the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center, the Weizmann Institute of Science in Israel, and Sheba Medical Center in Israel.

9 Oct 2009

Angiochem to announce clinical study results of ANG1005 drug

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that clinical data for its lead drug candidate, ANG1005, for the treatment of brain cancers, as well as data showing how compounds from Angiochem’s Engineered Peptide Compounds (EPiC) platform are capable of crossing the blood-brain barrier will be highlighted at the Society for Neuroscience Annual Meeting in Chicago on October 17-21, 2009.

8 Oct 2009

American Shared Hospital Services updates on Todd Cancer Institute's proton therapy center development

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today shared a recent announcement regarding progress in the development of a proton therapy center at Todd Cancer Institute at Long Beach Memorial Medical Center.

8 Oct 2009

Valensa initiates licensing patent for the use of the astaxanthin as a dietary supplement

Valensa International (Orlando, FL USA) announced today that it has initiated a broad out licensing effort for University of Illinois patent (US 5,527,533 and its foreign equivalents) for the use of the astaxanthin in eye healthcare dietary supplement applications.

8 Oct 2009

MUSC enrolls first patient in the Stroke Treatment And Revascularization Therapy trial

The Stroke Team at the Medical University of South Carolina (MUSC) in Charleston, SC, including Aquilla Turk, DO, Associate Professor of Radiology, M. Imran Chaudry, MD, Assistant Professor of Radiology, and Raymond D. Turner IV, MD, Assistant Professor of Neurosurgery and Radiology, enrolled the first patient in the Stroke Treatment And Revascularization Therapy (START) trial.

8 Oct 2009

New Leaf Brands' initiative to find cure for MS, will sponsor a participating team for bike ride event

New Leaf Brands, a wholly owned subsidiary of Baywood International, Inc. (OTCBB: BAYW) ("Company"), today announced that the Company will sponsor a participating team in the Multiple Sclerosis/Tappan Zee Bike Ride taking place on Sunday, October 18, 2009 in Tarrytown, New York.

8 Oct 2009

First Edition: October 8, 2009

Today's headlines reflect yesterday's big health reform news: The CBO's revised cost analysis is good news for the Baucus bill.

8 Oct 2009

Brain News and Research

Further Reading

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

Hyper-SAGE with MRI sensitivity, a promising tool for in vivo diagnostics and molecular imaging

Three hundred participants sought for world-first study to determine shared biological basis for psychotic illnesses

Learning new tasks causes changes in spontaneous brain activity patterns: Study

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

NIH grant to the University of Central Florida to conduct research on aphasia

Hispanic children with brain tumors rarely get high-quality treatment than other children: Study

New York Governor participates in roundtable discussion on stem cell research

TGen selected to conduct cancer experiments using advanced computer simulations

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Therapeutic hypothermia after CPR improves survival and lessens brain damage

Study raises concerns on long-term consequences of neonatal caffeine administration on brain development

New findings highlight potential role of copper in Alzheimer's disease

Premature aging of immune system develops amyotrophic lateral sclerosis

Angiochem to announce clinical study results of ANG1005 drug

American Shared Hospital Services updates on Todd Cancer Institute's proton therapy center development

Valensa initiates licensing patent for the use of the astaxanthin as a dietary supplement

MUSC enrolls first patient in the Stroke Treatment And Revascularization Therapy trial

New Leaf Brands' initiative to find cure for MS, will sponsor a participating team for bike ride event

First Edition: October 8, 2009

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News